NasdaqGS - Nasdaq Real Time Price • USD
United Therapeutics Corporation (UTHR)
As of 12:41 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 11 | 12 | 12 |
| Avg. Estimate | 6.28 | 6.42 | 24.24 | 26.46 |
| Low Estimate | 5.67 | 5.61 | 21.38 | 21.67 |
| High Estimate | 7.47 | 7.77 | 28.89 | 37.65 |
| Year Ago EPS | 5.24 | 5.38 | 19.81 | 24.24 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 12 | 12 |
| Avg. Estimate | 680.32M | 701.22M | 2.73B | 2.96B |
| Low Estimate | 647.5M | 663M | 2.59B | 2.62B |
| High Estimate | 728.56M | 760.57M | 2.93B | 3.41B |
| Year Ago Sales | -- | 609.4M | 2.33B | 2.73B |
| Sales Growth (year/est) | -- | 15.10% | 17.50% | 8.20% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 4.5 | 5.04 | 4.19 | 5.65 |
| EPS Actual | 5.24 | 5.38 | 4.36 | 6.17 |
| Difference | 0.74 | 0.34 | 0.17 | 0.52 |
| Surprise % | 16.40% | 6.70% | 4.10% | 9.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 6.28 | 6.42 | 24.24 | 26.46 |
| 7 Days Ago | 6.27 | 6.38 | 24.3 | 26.38 |
| 30 Days Ago | 6.09 | 6.31 | 24.04 | 24.86 |
| 60 Days Ago | 6.08 | 6.26 | 23.95 | 24.6 |
| 90 Days Ago | 5.76 | 6.05 | 22.13 | 24.21 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 10 | 6 | 9 | 8 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | UTHR | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 19.80% | -- | -- | 8.40% |
| Next Qtr. | 19.30% | -- | -- | 11.90% |
| Current Year | 22.40% | -- | -- | 5.60% |
| Next Year | 9.20% | -- | -- | 13.00% |
| Next 5 Years (per annum) | 9.70% | -- | -- | 11.05% |
| Past 5 Years (per annum) | 17.58% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Goldman Sachs: Neutral to Neutral | 5/3/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 5/2/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/2/2024 |
| Maintains | Wells Fargo: Overweight to Overweight | 3/7/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 2/22/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/22/2024 |
Related Tickers
LQDA Liquidia Corporation
12.27
+1.72%
MNKD MannKind Corporation
4.3950
+1.74%
ALNY Alnylam Pharmaceuticals, Inc.
150.94
+0.31%
HALO Halozyme Therapeutics, Inc.
43.80
+1.51%
JAZZ Jazz Pharmaceuticals plc
112.72
+2.82%
BMRN BioMarin Pharmaceutical Inc.
80.83
-0.25%
INCY Incyte Corporation
57.19
+7.77%
ARGX argenx SE
365.51
-2.44%
GMAB Genmab A/S
29.30
+1.60%
BPMC Blueprint Medicines Corporation
106.55
-0.15%